EGFR and thyroid gland papillary carcinoma: This effect was particularly pronounced in RET-rearranged papillary thyroid cancer cells, where early EGFR activation reduced sensitivity to RET inhibitors, and targeting EGFR with afatinib significantly enhanced the response.